The following information was filed by Sensei Biotherapeutics, Inc. (SNSE) on Thursday, March 25, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. Get the latest Sensei Biotherapeutics Inc (SNSE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today … The Company is engaged in the discovery and development of therapies with focus on treatments for cancer. Dr. English will serve as a Class III director whose term will expire at the 2024 annual meeting of stockholders. Who bought or sold SENSEI BIOTHERAPEUTICS INC this quarter? SNSE 11.94 0.08 (0.68%). Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation of … Monitor SEC Form 4 Insider Trading Filings for Insider Buying and Selling. Wednesday, May 12, 2021 The Company is engaged in the discovery and development of therapies with focus on treatments for cancer. James Peyer is currently the largest shareholder, with 16% of shares outstanding. It offers SNS-301 and SNS-723 cancer vaccines. The stock price of Sensei Biotherapeutics Inc (NASDAQ: SNSE) – a clinical-stage immunotherapy company focused on the discovery and development of next-generation therapeutics for … Sensei Biotherapeutics has raised a total of $58.5M in funding over 2 rounds. Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company’s stock price has collected 24.12% of gains in the last five trading sessions. Sensei Biotherapeutics Inc (SNSE) $11.83 0.23 (1.91%) 16:00 EDT SNSE Stock Quote Delayed 30 Minutes 7 Stocks With Significant Insider Buying. Compare. Sensei Biotherapeutics, Inc. is regulated by the U.S. Security and Exchange Commission and incorporated in the state of Delaware. SNSE 11.94 0.08 (0.68%). Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board. SENSEI BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except share and per share data) March 31, 2021 . The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a … 12.43 +0.05 +0.40% Official Close 5/28/2021 NAS. Add to watchlist Start Trading >> Plus500. Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, announced the pricing of its upsized initial public offering of 7,000,052 shares of common stock at … Sensei Biotherapeutics Inc SNSE Morningstar%2c Inc. 5/28/2021 Sensei Biotherapeutics Reports First Quarter 2021 … Name and Address of Reporting Person * English Jessie: 2. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a … The Company is engaged in the discovery and development of therapies with focus on treatments for cancer. BOSTON and ROCKVILLE, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the full year ended 2020 and provided … Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck GlobeNewswire. Use the Zacks Rank and Style Scores to find out is SNSE is right for your portfolio. Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of … Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company. 8 Corp., dated as of October 22, 2020 from Sensei Biotherapeutics, Inc… In the medium term (3months), SNSE's stock price should underperform the … Sensei Biotherapeutics, Inc. Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. Lease Agreement, by and between Sensei Biotherapeutics, Inc. and Are-Maryland No. Payout History. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a … On April 1, 2021, the board of directors (the "Board") of Sensei Biotherapeutics, Inc. (the "Company") appointed Jessie M. English, Ph.D. to serve as a director of the Company. Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company. 76.4% of retail CFD accounts lose money. The current price level -52.23% lower than the highest price of $26.50 marked by the stock while trading over the past 52-weeks, whereas it is 39.89% higher than the lowest price of $9.05 the company dropped to over past 52-weeks. The Company is engaged in the discovery and development of therapies with focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated … Sensei Biotherapeutics is a clinical-stage biopharmaceutical company engaged in discovery, development, and delivery of next generation immunotherapies with an initial focus on treatments for cancer. Item 2.02 Results of Operations and Financial Condition. Presently, Sensei Biotherapeutics Inc. shares are logging -52.23% during the 52-week period from high price, and 39.89% higher than the lowest price point for the same timeframe. On May 12, 2021, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the three months ended March 31, 2021. Insider trades for Sensei Biotherapeutics, Inc. (SNSE). Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company. Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Cambrian Biopharma Inc purchased 2,183 shares of the stock in a transaction dated Monday, March 22nd. The … Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board. Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. Sensei Biotherapeutics, Inc., a clinical-stage cancer immunotherapy company, today announced the successful closing of a $30 million Series B financing. Company Releases for Sensei Biotherapeutics Inc. Wednesday, May 19, 2021. Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings) IRS No. Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The Company is engaged in the discovery and development of therapies with focus on treatments for cancer. Sensei Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended, and forms of agreements thereunder (Filed With SEC on January 15, 2021) Stock Purchase Agreement, by and among Sensei Biotherapeutics, Inc. and the stockholders of Alvaxa Biosciences, Inc., dated as of May 18, 2020 (Filed With … Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the … Reviews (240) 243-8000 Website. May 12, 2021 Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update - ImmunoPhage™ platform programs and the VISTA program continue to advance - - New safety and efficacy data from ongoing Phase 1/2 combination study of SNS-301 in squamous cell carcinoma of the head and … The Company focuses in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Sensei Biotherapeutics, Inc. (NASDAQ:SNSE)’s Biggest Investors. Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. View Sensei Biotherapeutics, Inc. SNSE investment & stock information. View today's stock price, news and analysis for Sensei Biotherapeutics Inc. (SNSE). Sensei Biotherapeutics is registered under the ticker NASDAQ:SNSE . Press Release reported on 05/19/21 that Sensei Biotherapeutics Announces New … Menu & Reservations Make Reservations . Long and Short Trading Ideas using Insider Transaction Data. This is why it happened. Sensei Biotherapeutics, Inc is primarely in the business of pharmaceutical preparations. Trading Ideas. Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company. He has 18 years of research and development experience from Zenith Epigenetics Ltd, Igenica Biotherapeutics Inc., OncoMed Pharmaceuticals, Tularik, Inc. (now Amgen) and … Sensei Biotherapeutics, Inc. (1829802) SEC Filing S-1 IPO report for the period ending Friday, January 15, 2021 : 000000000 | State of Incorp. BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointments of Maura Gillison, M.D., Ph.D.,Read … 267 Sensei Biotherapeutics, Inc. insiders own 8.18% of total outstanding shares while institutional holders control 19.18%, with the float percentage being 20.89%. Sensei Biotherapeutics, Inc. operates as a clinical-stage immunotherapy company. Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. 1. : 000000000 | State of Incorp. The Company is engaged in the discovery and development of therapies with focus on treatments for cancer. Dr. English will serve as a Class III director whose term will expire at the 2024 annual meeting of stockholders. 267 Sensei Biotherapeutics. Edward van der Horst is a molecular pharmacologist with a strong focus on antibody drug development across diverse target classes in oncology. Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. Date of Event Requiring Statement (MM/DD/YYYY) 4/1/2021 : 3. Real-time Insider Trading Stock Screener. Home Dividend Stocks Health Care Biotech Pharma Large Pharma Sensei Biotherapeutics Inc (SNSE) Overview. Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck GlobeNewswire. The Company is engaged in the discovery and development of therapies with focus on treatments for cancer. Sensei Biotherapeutics, Inc, a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. For financial reporting, their fiscal year ends on December 31st. Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company. New. Company Profile. Assets . Sensei Biotherapeutics is a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Find the latest Sensei Biotherapeutics, Inc. (SNSE) stock quote, history, news and other vital information to help you with your stock trading and investing. Their latest funding was raised on Jan 11, 2021 from a Series B round. Sensei Biotherapeutics, Inc. Common Stock (SNSE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Citadel Advisors LLC is the largest shareholder of the company, while 56 institutions own … Its ImmunoPhage platform is a self-adjuvanted and differentiated immunotherapy approach that is designed to utilize bacteriophage … Sensei Biotherapeutics story: Sensei Biotherapeutics Inc gains 02540 percent for June 10 Equitiescom and other headlines for Sensei Biotherapeutics Sensei Biotherapeutics Inc (NQ: SNSE ) 11.99 +0.13 (+1.10%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2021 Add to My Watchlist. Current assets: Cash and cash equivalents $ … Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings) IRS No. 08:09 PM ET. January 11, 2021. Sensei Biotherapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View today's stock price, news and analysis for Sensei Biotherapeutics Inc. (SNSE). BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and … Get the latest Sensei Biotherapeutics, Inc. SNSE detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The Company is engaged in the discovery and development of therapies with focus on treatments for cancer. Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform. Their stock opened with $19.00 in its Feb 3, 2021 IPO. On March 25, 2021, Sensei Biotherapeutics, Inc. (the “Registrant”) issued a press release announcing its financial results for the year ended December 31, 2020.This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. Sensei Biotherapeutics Inc Dividend policy None Price as of: JUN 07, 12:00 PM EDT $12.07 -0.17 -1.39% Watchlist Overview. Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company. Share your opinion and gain insight from … Company Releases for Sensei Biotherapeutics Inc. Wednesday, May 19, 2021. Quote. Sensei Biotherapeutics serves customers in the United States. Find the latest Sensei Biotherapeutics, Inc. (SNSE) stock discussion in Yahoo Finance's forum. Should I buy Sensei Biotherapeutics, Inc. (SNSE)? The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. Its ImmunoPhage platform is a self-adjuvanted and differentiated immunotherapy approach that is designed to utilize bacteriophage … : 000000000 | State of Incorp. Sensei Biotherapeutics is a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. General Information: Business: We are a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. The stock’s price range for the 52-week period managed to maintain the performance between $9.05 and $26.50. December 31, 2020 . Sensei Biotherapeutics is not owned by hedge funds. Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. Sensei Biotherapeutics, Inc. operates as a clinical-stage immunotherapy company. View SNSE financial statements in full. Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings) IRS No. Sensei Biotherapeutics, Inc 1405 Research Blvd Rockville MD 20850. SNSE stock forecast Our latest prediction for Sensei Biotherapeutics Inc's stock price was made on the May 5, 2021 when the stock price was at 12.08$.. Sensei Biotherapeutics Inc. (SNSE) saw an uptrend of 30.11% in the recent trading with $12.66 being its most recent. Sensei Biotherapeutics Inc NASDAQ Updated Jun 11, 2021 7:31 PM. Sensei Biotherapeutics is a clinical-stage biopharmaceutical company engaged in discovery, development, and delivery of next generation immunotherapies with … Print. Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company. Sensei Biotherapeutics Inc. (NASDAQ:SNSE) went up by 30.11% from its latest closing price compared to the recent 1-year high of $26.50. Issuer Name and Ticker or Trading Symbol Sensei Biotherapeutics, Inc. [SNSE] (Last) (First) (Middle) C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., SUITE 125 News & Research. Sensei Biotherapeutics, Inc. operates as a clinical-stage immunotherapy company. Sensei Biotherapeutics Inc NASDAQ Updated Jun 11, 2021 7:31 PM. 08:09 PM ET The stock price of Sensei Biotherapeutics Inc (NASDAQ: SNSE) increased by 30.11% today. Sensei Biotherapeutics Inc Stock , SNSE. Sensei Biotherapeutics Inc. is working on an initial public offering in the U.S. that could value the cancer drug developer at $500 million, according to people familiar with the matter. In the short term (2weeks), SNSE's stock price should outperform the market by 1.64%.During that period the price should oscillate between -10.41% and +14.45%.. By Mark Putrino, CMT Mar 9, 2021 Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company. Payout Estimate. Get directions, reviews and information for Sensei Biotherapeutics, Inc in Rockville, MD. Sensei Biotherapeutics is funded by 10 investors. On April 1, 2021, the board of directors (the "Board") of Sensei Biotherapeutics, Inc. (the "Company") appointed Jessie M. English, Ph.D. to serve as a director of the Company. Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and … View the latest Sensei Biotherapeutics Inc. (SNSE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Srixon Ad333 Golf Balls Yellow, La Belle Province Montreal, Konstanten Best Class, Imagery In A Supermarket In California, Difference Between Forehand And Backhand Grip Badminton, Seo Kang Joon Enlistment Date, Wilkins Villanueva Biography, Oakland Farmers Market, Benefits Of Getting Along With Others,